Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Savara Inc. is headquartered in Austin, Texas.